Report
Dominic Rose ...
  • Naresh Chouhan
EUR 4773.50 For Business Accounts Only

Global Bioprocessing - 5% Mid-Term Trend Growth (12pgs)

We show clear evidence that rapidly improved yields are the missing link in the mystery of the Bioprocessing slowdown. New analysis using our proprietary biologic demand model shows that industry trend growth could have fallen to just 5% & higher yields explain the slow recovery & poor visibility. We believe trend growth is now MSD 2024-26, at best. We will attend the biggest Bioprocessing trade conference next week to better understand complex industry trends & the feasibility of rapid yield improvements. Should we find a ‘smoking gun’, the entire Bioprocessing space could face downgrades to current cons. estimates for 11% & 12% sales growth in ‘25 & ’26, respectively. Lonza D/G to HOLD following our analysis.
For access to the full note, please contact Naresh Chouhan ( )
Underlyings
Lonza Group AG

Lonza supplies services and products that range from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions. Co. operates in two segments: Lonza Pharma & Biotech, which clusters all of Co.'s offerings for pharmaceutical markets, focuses on providing custom development, custom manufacturing, cell therapy, viral therapeutics and bioscience solutions; and Lonza Specialty Ingredients, which includes offerings in its consumer care, agro ingredients, industrial solutions, wood protection and water treatment.

Sartorius Stedim Biotech SA

Sartorius Stedim Biotech is a provider of equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Co.'s solutions cover fermentation, filtration, purification, fluid management and lab technologies and membrane chromatography, including various conventional lab products to biopharmaceutical laboratories. Co.'s technologies, products and services are used to develop and manufacture medications and vaccines using biological methods. Co.'s products covers all upstream and downstream steps in the production of active pharmaceutical ingredients. It specializes in single-use products and offers technical consulting and services.

Provider
New Street Research
New Street Research

Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.

New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:

  • Pan European Telecom Services and Cable
  • US Telecoms, Cable, Satellite and Towers
  • Global Emerging Market Telecoms
  • Japan Telecoms
  • Asian Internet
  • Pan European Healthcare
  • Global healthcare thematic research

We provide debt research on:

  • Pan European Telecom Services and Cable


Analysts
Dominic Rose

Naresh Chouhan

Other Reports on these Companies
Other Reports from New Street Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch